Page 58 - Read Online

Vojdeman et al. J Transl Genet Genom 2021;5:182-88 https://dx.doi.org/10.20517/jtgg.2021.03 Page 188

lymphocytic leukaemia. Br J Haematol 2013;163:496-500. DOI PubMed
9. Eichhorst B, Fink A, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine,
cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label,
randomised, phase 3, non-inferiority trial. Lancet Oncol 2016;17:928-42. DOI PubMed
10. Jeromin S, Haferlach C, Dicker F, Alpermann T, Haferlach T, Kern W. Differences in prognosis of stereotyped IGHV3-21 chronic
lymphocytic leukaemia according to additional molecular and cytogenetic aberrations. Leukemia 2016;30:2251-3. DOI PubMed
11. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7,
MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28:108-17. DOI PubMed
12. Baliakas P, Agathangelidis A, Hadzidimitriou A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic
considerations. Blood 2015;125:856-9. DOI PubMed PMC
13. Bhoi S, Ljungström V, Baliakas P, et al. Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of
subset #2. Epigenetics 2016;11:449-55. DOI PubMed PMC
14. Baliakas P, Mattsson M, Hadzidimitriou A, et al. No improvement in long-term survival over time for chronic lymphocytic leukemia
patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica 2018;103:e158-61. DOI PubMed
PMC